Summary
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to address longstanding unmet needs in bleeding control. Uncontrolled bleeding is a major intraoperative issue and postoperative complication with high economic impacts, increasing procedural costs up to $30,000. Of 1.6 million surgical procedures in the US, 15% or 240,000 patients underwent re-operation due to lack of hemostasis. Post-operative bleeding results in 2-3 times longer hospital stay (15 vs 6 days), 6 times longer ICU stay (6 vs 1 days) and increased costs of 3-4 times ($40k
